Mats Hardling

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Not all imatinib resistance in CML are BCR-ABL kinase domain mutations

Yuan Wei, Mats Hardling, Bob Olsson et al. · Annals of Hematology · 2006 · 29 citations

Medicine, Molecular Biology, Oncology +9

Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial

Jan‐Erik Johansson, John Bratel, Mats Hardling et al. · Bone Marrow Transplantation · 2019 · 29 citations

Pharmacy, Immunology, Cell Therapy +16

An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients

Hareth Nahi, H Hägglund, Tomas Ahlgren et al. · Haematologica · 2008 · 20 citations · Full text

Life Sciences, Hematology, Oncology +17

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial

Ingrid Jakobsen Falk, Johan Lund, Henrik Gréen et al. · Cancer Chemotherapy and Pharmacology · 2017 · 18 citations · Full text

Medicine, Genetics, Pharmacology +15